NAS
CAPR icon

Nykredit A/S’s Capricor Therapeutics CAPR Stock Holding History

Nykredit A/S’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.5K Buy
+645
New +$19.6K ﹤0.01% 1794

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DCM
DG Capital Management New York $475M AUM 36.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Nykredit A/S's CAPR Position: Q2 2026 in Review

Nykredit A/S opened a new position in Capricor Therapeutics (CAPR) in Q2 2026: 645 shares worth $15.5K. The stake represents ﹤0.01% of the portfolio and ranks #1794 among its holdings.

105 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Nykredit A/S held 645 shares of Capricor Therapeutics worth $15.5K as of Q2 2026.
  • Capricor Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Capricor Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1794 holding.
  • 105 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.